Archive for PD-L1

Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 in Patients with Advanced or Metastatic Solid Tumors

A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

A first-in-human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solid tumors expressing B7-H6

A Phase 1 Open-label, Multicenter, Dose-Ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1